共 40 条
Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts
被引:152
作者:
Kapitonov, Dmitri
[1
]
Allegood, Jeremy C.
[1
]
Mitchell, Clint
[1
]
Hait, Nitai C.
[1
]
Almenara, Jorge A.
[2
,3
]
Adams, Jeffrey K.
[4
]
Zipkin, Robert E.
[4
]
Dent, Paul
[1
]
Kordula, Tomasz
[1
]
Milstien, Sheldon
[1
]
Spiegel, Sarah
[1
]
机构:
[1] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA 23298 USA
[3] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA
[4] Enzo Life Sci Int Inc, Pymouth Meeting, PA USA
关键词:
GLIOMA-CELLS;
TUMOR-CELLS;
SPHINGOSINE-1-PHOSPHATE;
SURVIVAL;
MIGRATION;
PROGRESSION;
EXPRESSION;
MULTIFORME;
RECEPTORS;
PATHWAY;
D O I:
10.1158/0008-5472.CAN-09-0664
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Sphingosine-1-phosphate is a potent sphingolipid mediator of diverse processes important for brain tumors, including cell growth, survival, migration, invasion, and angiogenesis. Sphingosine kinase 1 (SphK1), one of the two isoenzymes that produce sphingosine-1-phosphate, is up-regulate in glioblastoma and has been linked to poor prognosis in patients with glioblastoma multiforme (GBM). In the present study, we found that a potent isotype-specific SphK1 inhibitor, SK1-I, suppressed growth of LN229 and U373 glioblastoma cell lines and nonestablished human GBM6 cells. SK1-I also enhanced GBM cell death and inhibited their migration and invasion. SK1-I rapidly reduced phosphorylation of Akt but had no significant effect on activation of extracellular signal-regulated kinase 1/2, another important survival pathway for GBM. Inhibition of the concomitant activation of the c-Jun-NH2-kinase pathway induced by SK1-I attenuated death of GBM cells. Importantly, SK1-I markedly reduced the tumor growth rate of glioblastoma xenografts, inducing apoptosis and reducing tumor vascularization, and enhanced the survival of mice harboring LN229 intracranial tumors. Our results support the notion that SphK1 may he an important factor in GBM and suggest that an isozyme-specific inhibitor of SphK1 deserves consideration as a new therapeutic agent for this disease. [Cancer Res 2009;69(17):6915-23]
引用
收藏
页码:6915 / 6923
页数:9
相关论文

